Literature DB >> 18055804

Potential role of Rho-associated protein kinase inhibitor Y-27632 in glaucoma filtration surgery.

Megumi Honjo1, Hidenobu Tanihara, Takanori Kameda, Takahiro Kawaji, Nagahisa Yoshimura, Makoto Araie.   

Abstract

PURPOSE: To investigate the role of Y-27632, a specific inhibitor of Rho-associated protein kinase (ROCK) in regulating human Tenon fibroblast (HTF) activities including proliferation, adhesion, contraction, migratory response, and myofibroblast transdifferentiation. Effects of Y-27632 on prevention of postoperative scar formation were also examined in a rabbit model of glaucoma filtration surgery.
METHODS: After treatment of HTFs with Y-27632, cell toxicity, proliferation, migration, adhesion, and contraction were studied. The cytoskeleton and alpha-smooth muscle actin (alpha-SMA) expression were examined via immunohistochemistry. In vivo studies in Japanese white rabbits consisted of a full-thickness sclerostomy followed in the 7-day postoperative period by topical application of Y-27632. Intraocular pressure, morphologic changes in bleb features, and histology of surgical sites were evaluated.
RESULTS: Y-27632 had no direct toxicity or significant effects on cell proliferation of HTF. The cell adhesion assay showed that Y-27632 promoted adhesiveness to both fibronectin and collagen type I. Use of Y-27632 significantly inhibited collagen gel contraction and alpha-SMA expression in HTFs. Y-27632 also increased HTF motility. In vivo, Y-27632 inhibited wound healing and fibroproliferation after filtration surgery and significantly improved surgical outcome compared with the vehicle. Histologic examination revealed that blebs in the Y-27632-treated group differed from those in the vehicle-treated group in that they lacked significant collagen deposition in the sclerostomy area.
CONCLUSIONS: Y-27632 had profound effects on activities of HTFs and was effective in preventing fibroproliferation and scar formation in a rabbit model of glaucoma surgery. A ROCK inhibitor may be an effective anti-scarring agent after glaucoma filtering surgery.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18055804     DOI: 10.1167/iovs.07-0878

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  40 in total

Review 1.  Discovery of Molecular Therapeutics for Glaucoma: Challenges, Successes, and Promising Directions.

Authors:  Rebecca K Donegan; Raquel L Lieberman
Journal:  J Med Chem       Date:  2015-09-25       Impact factor: 7.446

2.  Effects of ROCK inhibitor, Y-27632, on adhesion and mobility in esophageal squamous cell cancer cells.

Authors:  Lili Wang; Lexun Xue; Hongxia Yan; Jie Li; Yucheng Lu
Journal:  Mol Biol Rep       Date:  2009-08-02       Impact factor: 2.316

Review 3.  Rho kinase inhibitors-a review on the physiology and clinical use in Ophthalmology.

Authors:  Nuno Moura-Coelho; Joana Tavares Ferreira; Carolina Pereira Bruxelas; Marco Dutra-Medeiros; João Paulo Cunha; Rita Pinto Proença
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2019-03-07       Impact factor: 3.117

Review 4.  Myofibroblast transdifferentiation: The dark force in ocular wound healing and fibrosis.

Authors:  Daisy Y Shu; Frank J Lovicu
Journal:  Prog Retin Eye Res       Date:  2017-08-12       Impact factor: 21.198

Review 5.  Impact of the clinical use of ROCK inhibitor on the pathogenesis and treatment of glaucoma.

Authors:  Megumi Honjo; Hidenobu Tanihara
Journal:  Jpn J Ophthalmol       Date:  2018-02-14       Impact factor: 2.447

Review 6.  Overview of cicatricial modulators in glaucoma fistulizing surgery.

Authors:  Camille Moura de Oliveira; Juliana de Lucena Martins Ferreira
Journal:  Int Ophthalmol       Date:  2020-06-05       Impact factor: 2.031

7.  Effects of 0.4% ripasudil hydrochloride hydrate on morphological changes in rabbit eyes.

Authors:  Bundit Limratchatamorn; Ken Asakawa; Kimiyo Mashimo; Shigekazu Uga; Hitoshi Ishikawa
Journal:  Int J Ophthalmol       Date:  2019-10-18       Impact factor: 1.779

8.  Topical administration of a Rock/Net inhibitor promotes retinal ganglion cell survival and axon regeneration after optic nerve injury.

Authors:  Peter X Shaw; Alan Sang; Yan Wang; Daisy Ho; Christopher Douglas; Lara Dia; Jeffrey L Goldberg
Journal:  Exp Eye Res       Date:  2016-07-18       Impact factor: 3.467

Review 9.  Rho Kinase Inhibitors as a Novel Treatment for Glaucoma and Ocular Hypertension.

Authors:  Angelo P Tanna; Mark Johnson
Journal:  Ophthalmology       Date:  2018-07-12       Impact factor: 12.079

10.  A chemical biology screen reveals a role for Rab21-mediated control of actomyosin contractility in fibroblast-driven cancer invasion.

Authors:  S Hooper; C Gaggioli; E Sahai
Journal:  Br J Cancer       Date:  2009-12-01       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.